NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase – Still a Buy?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) saw strong trading volume on Monday . 802,951 shares were traded during mid-day trading, an increase of 14% from the previous session’s volume of 703,258 shares.The stock last traded at $33.9350 and had previously closed at $35.46.

Analyst Ratings Changes

NAMS has been the topic of several research reports. Needham & Company LLC lifted their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Stifel Nicolaus boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Guggenheim lifted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.55.

NewAmsterdam Pharma Price Performance

The firm’s 50 day moving average price is $34.06 and its 200-day moving average price is $33.06. The stock has a market cap of $3.80 billion, a P/E ratio of -19.07 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insider Activity at NewAmsterdam Pharma

In other news, CEO Michael H. Davidson sold 183,332 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.71, for a total transaction of $6,180,121.72. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,870,394.24. The trade was a 51.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 45,481 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the transaction, the insider owned 53,500 shares in the company, valued at approximately $1,889,085. This trade represents a 45.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 650,421 shares of company stock valued at $22,417,631 over the last ninety days. Insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its position in shares of NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the period. Wells Fargo & Company MN raised its holdings in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Mather Group LLC. purchased a new position in NewAmsterdam Pharma during the third quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in NewAmsterdam Pharma during the third quarter valued at about $30,000. Finally, Navalign LLC purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth about $46,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.